October 2nd 2023
In a cross-study analysis, omaveloxolone slowed progression in FA by at least 50% each year for 3 years compared with corresponding data from an external control group in a natural history study.
Recognizing Rett Syndrome Early to Improve Long-Term Management Outcomes
Register Now!
Shaping the Management of Multiple Sclerosis – The Potential for BTK Inhibitors in Clinical Practice
View More
Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
10/13/2023
Register Now!
From Clinical Trials to Clinical Practice – Incorporating Screening and Assessment Strategies for the Early Diagnosis of Alzheimer Disease
View More
Taking Pompe Disease Management to the Next Level: Optimizing Clinical Assessments and Treatment Decision-Making
View More
Addressing Healthcare Inequities in Stroke Care: How Can We Play an Active Role in Improving Outcomes for All Patients?
View More
2022 4th Annual International Congress on the Future of Neurology
View More
Understanding Best Care Practices for Hemorrhagic Stroke – A Focus on the Role of DOAC Reversals
View More
Neuro News Roundup: LGMD Awareness Day – Expert Insight and Latest Literature
September 30th 2023In honor of Limb-Girdle Muscular Dystrophy Awareness Day, held September 30, 2023, get caught up on some of the latest news in LGMD, with data updates and expert insights all in one place from the NeurologyLive® team.
FDA Approves Cipaglucosidase Alfa and Miglustat as First Two-Component Therapy for Pompe Disease
In a phase 3 setting, the 2-component therapy showed positive trends or clinically meaningful improvements on motor and respiratory functions compared with previously approved enzyme replacement therapy.
Clinical Insights on the Emerging Trends in Research for NMOSD and MOGAD
September 29th 2023Erin Longbrake, MD, PhD, associate professor of neurology at Yale School of Medicine, discussed the importance of understanding rare autoimmune disorders to effectively design clinical trials and treatment strategies, especially for heterogeneous conditions like NMOSD and MOGAD.
NeurologyLive® Clinician of the Month Spotlight: Peter B. Kang, MD, FAAN, FAAP
September 28th 2023As part of our monthly clinician spotlight, NeurologyLive® highlighted stroke expert Peter Kang, MD, director of the Paul and Sheila Wellstone Muscular Dystrophy Center and professor of neurology at the University of Minnesota.
Disparities in Memory Clinic Visits and Dementia Severity Identified in Disadvantaged Neighborhoods
September 28th 2023Patients who self-identified as Black and were living in less affluent neighborhoods were less likely to be seen in one large memory clinic as well as have more severe dementia at initial visit.
Standard and Nonstandard Physical Therapy Show Similar Effectiveness for Parkinson Disease
September 26th 2023Although research supports the use of physical therapy as an effective treatment for Parkinson disease, implementation factors including type, timing, frequency, and durability of outcomes remain mainly untouched.
New Interim Data Reported on DNL310 for Hunter Syndrome Treatment in Phase 1/2 Trial
September 26th 2023Additional biomarker findings from up to 2 years of DNL310 treatment suggest positive changes in adaptive behavior and cognition as well as improvement in auditory function among pediatric patients with Hunter syndrome.
CNM-Au8 Shows Significant Long-Term Survival Improvement in HEALEY ALS Platform Trial
September 25th 2023In an integrated meta-analysis of the HEALEY ALS platform trial and RESCUE-ALS trial, 30mg of CNM-Au8 resulted in 59% decreased risk of mortality among participants with ALS compared with PRO-ACT matched placebo over long-term follow-up.
Role of Gut Microbiome, Alpha Synuclein in the Prodromal Stage of Parkinson Disease
Virginia Gao, MD, PhD, a movement disorders fellow at Weill Cornell Medicine, discussed several topics related to the use of biomarkers in the prodromal stages of neurodegenerative disorders like Parkinson disease.
BXCL501 Meets Primary Efficacy End Point in Phase 3 TRANQUILITY II Trial of Alzheimer Agitation
September 23rd 2023Among 443 episodes in 149 patients treated with different doses of BXCL501 over 12 weeks, the 60 mcg dose showed a reduction in agitation for the first and all treated episodes at 1 and 2 hours.